CervoMed Inc. Common Stock
CRVOCervoMed Inc. (CRVO) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative and inflammatory diseases. The company leverages advanced scientific research to create novel treatment options aimed at improving patient outcomes in areas with significant unmet medical needs.
Company News
CervoMed presented Phase 2b trial results showing neflamapimod significantly slows clinical progression in dementia with Lewy bodies, with most prominent improvements in patients without AD co-pathology. The company plans to initiate Phase 3 trials in 2026.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Canaccord Genuity boosted the price target for CervoMed Inc. (NASDAQ: CRVO) from $50 to $65. Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rati...
